Volasertib, Boehringer Ingelheim Corporation´s Investigational Treatment Of Acute Myeloid Leukaemia, Is Granted “Orphan Drug Designation” In The EU And The U.S.

INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the US and UK only. Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) and the European Commission have granted volasertib* ‘orphan drug designation’ for the treatment of patients with acute myeloid leukaemia (AML).

Help employers find you! Check out all the jobs and post your resume.